ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 162 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2018. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $25,119 | -7.0% | 4,032 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $27,014 | +80.2% | 4,032 | +71.1% | 0.00% | 0.0% |
| Q2 2022 | $14,991 | -21.5% | 2,357 | -42.7% | 0.00% | 0.0% |
| Q1 2022 | $19,089 | -79.6% | 4,114 | -47.1% | 0.00% | 0.0% |
| Q3 2021 | $93,713 | -43.0% | 7,777 | 0.0% | 0.00% | -50.0% |
| Q2 2021 | $164,484 | -24.6% | 7,777 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $218,145 | +7.9% | 7,777 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $202,202 | -30.1% | 7,777 | 0.0% | 0.00% | -40.0% |
| Q3 2020 | $289,071 | -27.6% | 7,777 | 0.0% | 0.01% | -28.6% |
| Q2 2020 | $399,038 | +62.7% | 7,777 | 0.0% | 0.01% | +40.0% |
| Q1 2020 | $245,209 | -47.1% | 7,777 | 0.0% | 0.01% | -37.5% |
| Q4 2019 | $463,743 | +37.1% | 7,777 | -15.7% | 0.01% | +33.3% |
| Q3 2019 | $338,335 | -5.5% | 9,229 | +19.9% | 0.01% | 0.0% |
| Q2 2019 | $358,111 | +15.9% | 7,698 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $309,075 | -12.7% | 7,698 | 0.0% | 0.01% | -14.3% |
| Q4 2018 | $354,108 | +3.7% | 7,698 | 0.0% | 0.01% | +16.7% |
| Q3 2018 | $341,560 | -99.9% | 7,698 | 0.0% | 0.01% | +20.0% |
| Q2 2018 | $301,684,000 | -23.8% | 7,698 | +40.6% | 0.01% | -16.7% |
| Q1 2018 | $395,935,000 | +109881.9% | 5,474 | 0.0% | 0.01% | +20.0% |
| Q4 2017 | $360,000 | -34.1% | 5,474 | -49.8% | 0.01% | +66.7% |
| Q3 2017 | $546,000 | +8.3% | 10,896 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $504,000 | +30.9% | 10,896 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $385,000 | +323.1% | 10,896 | +17.7% | 0.00% | +200.0% |
| Q2 2016 | $91,000 | -42.0% | 9,258 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $157,000 | -23.8% | 9,258 | 0.0% | 0.00% | -50.0% |
| Q4 2015 | $206,000 | -5.5% | 9,258 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $218,000 | -71.2% | 9,258 | 0.0% | 0.00% | -60.0% |
| Q2 2015 | $757,000 | +54.2% | 9,258 | +74.4% | 0.01% | +25.0% |
| Q1 2015 | $491,000 | +128.4% | 5,307 | 0.0% | 0.00% | +300.0% |
| Q4 2014 | $215,000 | – | 5,307 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $27,840,842 | 18.82% |
| Ikarian Capital, LLC | 1,891,147 | $11,781,846 | 2.84% |
| Altium Capital Management LP | 620,000 | $3,862,600 | 1.96% |
| Ikarian Capital, LLC | 1,296,900 | $8,079,687 | 1.95% |
| Parkman Healthcare Partners LLC | 822,784 | $5,125,944 | 1.36% |
| Deep Track Capital, LP | 4,000,000 | $24,920,000 | 1.05% |
| Monaco Asset Management SAM | 470,100 | $2,928,723 | 0.88% |
| BRAIDWELL LP | 3,393,405 | $21,140,913 | 0.71% |
| Telemetry Investments, L.L.C. | 71,000 | $442 | 0.70% |
| Rhenman & Partners Asset Management AB | 900,000 | $5,607,000 | 0.58% |